百济神州的CDK4 抑制剂BGB-43395 进度处于前列,有望成为全球第二款进入注册临床阶段的CDK4 抑制剂根据公司指引,BGB-43395 预计在未来的 6-12 个月内进入注册临床阶段。BGB-43395 目前开展了3 项I 期临床,试验方案涵盖了单药或联合内分泌疗法( ET ,Endocrine Therapy)二线治疗,以及联合ET 和BCL2i 三线治疗HR+/HER2- BC。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.